Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9MCash on Hand
4.7mo Cash Runway
Follow BIVI by emailGet an email when BIVI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BIVI, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Aug 2026 · Phase 2 · Results Expected · NE3107 in Adults With Neurological Symptoms of Long COVID Registry primary completion date, not a results date
May 2026 · Phase 2 · Results Expected · A Study of NE3107 in Early Parkinson's Registry primary completion date, not a results date
Sep 2023 · Phase 3 · Results Expected · A Phase 3 Study of NE3107 in Probable Alzheimer's Disease Registry primary completion date, not a results date
Nov 2022 · Phase 1/2 · Results Expected · NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa Registry primary completion date, not a results date
Apr 2019 · Phase 2 · Results Expected · Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BIVI's own candidates): Terlipressin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BIVI holds $9M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.8M/quarter from operations,
an estimated runway of 4.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 5 months +40
ATM program on file since Sep 2026 +15
Shelf registration (S-3, Jun 2026) +10
Going-concern doubt in the latest 10-K +15These factors raise substantial doubt about our ability to continue as a going concern.10-K, Aug 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIVI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.